EMA Authorised: Abasaglar (previously Abasria) (insulin glargine) — Eli Lilly Nederland B.V.

View source ↗

Summary

EMA authorized Abasaglar, a biosimilar insulin glargine, for diabetes mellitus. The marketing authorization holder is Eli Lilly Nederland B.V.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diabetes Mellitus

Drugs mentioned

• Abasaglar (insulin glargine)

Snippet

Status: Authorised. Therapeutic area: Diabetes Mellitus. MAH: Eli Lilly Nederland B.V.. Decision date: 21/01/2026